Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sharon Stobert

Nurse Practitioner Cheswick, PA Nurse Practitioner

NPI 1013133032 CMS profile 10544683

105 Hill Ave, Cheswick, PA 15024

Open in the dashboard

General payments

$18,104

1,005 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sharon Stobert of Cheswick, PA is reported in the CMS Open Payments database as having received $18,104 across 1,005 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,461 164
2024 General $3,566 179
2023 General $3,674 218
2022 General $2,918 195
2021 General $4,485 249

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sharon Stobert
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Sharon Stobert were reported at $3,461. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Sharon Stobert Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $4,485 $135 $40–$426 $132
2022 $2,918 $152 $48–$470 $149
2023 $3,674 $166 $54–$529 $160
2024 $3,566 $173 $55–$556 $164
2025 $3,461 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $2,202 165 payments
  2. GlaxoSmithKline, LLC. $2,084 88 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,846 121 payments
  4. AstraZeneca Pharmaceuticals LP $1,606 37 payments
  5. Janssen Pharmaceuticals, Inc $1,594 67 payments
  6. AbbVie, Inc. $1,328 87 payments
  7. Lilly USA, LLC $1,082 71 payments
  8. Amgen Inc. $838 44 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $657 46 payments
  10. Daiichi Sankyo Inc. $522 37 payments
  11. Other $4,347 242 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $17,907 1,002 payments
  2. Education $197 3 payments
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $1,529 72 payments
  2. XARELTO $1,493 61 payments
  3. FARXIGA $1,255 15 payments
  4. JARDIANCE $1,176 76 payments
  5. UBRELVY $869 57 payments
  6. Ozempic $818 76 payments
  7. AIRSUPRA $814 14 payments
  8. RYBELSUS $769 74 payments
  9. BREZTRI $710 8 payments
  10. QULIPTA $699 46 payments
  11. Other $12,956 815 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 73 drugs

Part D claims

2,436

Median for Nurse Practitioner: 389

Drug cost

$240,692

Median for Nurse Practitioner: $21,885

Branded share of claims

23.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 58 $67,486
Eliquis Apixaban Brand 47 $50,546
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 65 $44,226
Jardiance Empagliflozin Brand 25 $20,175
Mounjaro Tirzepatide Brand 11 $12,807
Xarelto Rivaroxaban Brand 17 $12,014
Tresiba Flextouch U-200 Insulin Degludec Brand 13 $9,839
Albuterol Sulfate Hfa Albuterol Sulfate Brand 75 $1,686
Paxlovid Nirmatrelvir/Ritonavir Brand 35 $1,429
Atorvastatin Calcium Generic 150 $1,388

The 10 drugs with the highest cost, of 73 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$11,574

Of which drugs: $2,359

Medicare patients

82

Average age 74

Services billed

285

50 women, 32 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 52%
Ischemic heart disease 32%
Depression 24%
Diabetes 21%
Chronic kidney disease 20%
Heart failure 18%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 13 13 $1,064

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 44 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
$324 25 —
TRELEGY ELLIPTA
$249 65 —
AIRSUPRA
$248 — —
BREZTRI
$182 — —
Kerendia
$179 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 44 with Patron

Records

1,005 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record